CY1125340T1 - Ενωσεις και μεθοδοι για αντιμετωπιση βακτηριακων λοιμωξεων - Google Patents

Ενωσεις και μεθοδοι για αντιμετωπιση βακτηριακων λοιμωξεων

Info

Publication number
CY1125340T1
CY1125340T1 CY20221100157T CY221100157T CY1125340T1 CY 1125340 T1 CY1125340 T1 CY 1125340T1 CY 20221100157 T CY20221100157 T CY 20221100157T CY 221100157 T CY221100157 T CY 221100157T CY 1125340 T1 CY1125340 T1 CY 1125340T1
Authority
CY
Cyprus
Prior art keywords
compositions
methods
bacterial infections
treating bacterial
formula
Prior art date
Application number
CY20221100157T
Other languages
Greek (el)
English (en)
Inventor
Janelle Comita-Prevoir
Thomas Francois DURAND-REVILLE
Satenig GULER
Jan Romero
Mark Sylvester
Ruben Tommasi
Camilo VELEZ-VEGA
Xiaoyun Wu
Jing Zhang
Original Assignee
Entasis Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entasis Therapeutics, Inc. filed Critical Entasis Therapeutics, Inc.
Publication of CY1125340T1 publication Critical patent/CY1125340T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CY20221100157T 2017-05-08 2022-02-23 Ενωσεις και μεθοδοι για αντιμετωπιση βακτηριακων λοιμωξεων CY1125340T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762502867P 2017-05-08 2017-05-08
PCT/US2018/031593 WO2018208769A1 (en) 2017-05-08 2018-05-08 Compounds and methods for treating bacterial infections

Publications (1)

Publication Number Publication Date
CY1125340T1 true CY1125340T1 (el) 2024-02-16

Family

ID=62223332

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100157T CY1125340T1 (el) 2017-05-08 2022-02-23 Ενωσεις και μεθοδοι για αντιμετωπιση βακτηριακων λοιμωξεων

Country Status (27)

Country Link
US (1) US11046694B2 (enExample)
EP (1) EP3630111B1 (enExample)
JP (1) JP7058322B2 (enExample)
KR (1) KR102611447B1 (enExample)
CN (1) CN110709081B (enExample)
AU (1) AU2018266640B2 (enExample)
CA (1) CA3059773A1 (enExample)
CY (1) CY1125340T1 (enExample)
DK (1) DK3630111T3 (enExample)
EA (1) EA038393B1 (enExample)
ES (1) ES2907858T3 (enExample)
HR (1) HRP20220231T1 (enExample)
HU (1) HUE057592T2 (enExample)
IL (1) IL270380B (enExample)
LT (1) LT3630111T (enExample)
MA (1) MA48743A (enExample)
MX (1) MX385203B (enExample)
MY (1) MY201377A (enExample)
PE (1) PE20200333A1 (enExample)
PH (1) PH12019502509A1 (enExample)
PL (1) PL3630111T3 (enExample)
PT (1) PT3630111T (enExample)
SG (1) SG11201909443YA (enExample)
SI (1) SI3630111T1 (enExample)
SM (1) SMT202200110T1 (enExample)
TW (1) TWI791018B (enExample)
WO (1) WO2018208769A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3833665T3 (da) 2018-08-09 2023-10-09 Antabio Sas Diazabicyclooctanoner som hæmmere af serin-beta-lactamaser
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN111675641B (zh) * 2020-06-04 2023-09-08 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺类化合物、单环内酰胺类化合物盐及其制备方法
EP4146651A4 (en) 2021-05-07 2024-06-05 Ningxia Academy of Agriculture and Forestry Sciences SULFONYLAMIDINE SUBSTITUTED COMPOUNDS AND THEIR USE AS BETA-LACTAMASE INHIBITORS
US11814385B2 (en) 2021-06-25 2023-11-14 University Of South Florida Small molecule inhibitors targeting Clostridioides difficile sporulation
WO2025064681A1 (en) * 2023-09-19 2025-03-27 Entasis Therapeutics Inc. Compounds and methods for treating bacterial infections

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018129A1 (en) 1993-12-29 1995-07-06 Pfizer Inc. Diazabicyclic neurokinin antagonists
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US7507727B2 (en) * 2003-04-07 2009-03-24 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs and methods of using thereof
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
JP5038509B2 (ja) 2008-01-18 2012-10-03 メルク・シャープ・エンド・ドーム・コーポレイション β−ラクタマーゼ阻害剤
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP2135959A1 (en) 2008-06-19 2009-12-23 Novexel Use of (1R,2S,5R) 1,6-Diazabicyclo [3,2,1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2937034B1 (fr) * 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
AU2011373912B2 (en) 2011-07-26 2016-09-29 Wockhardt Limited Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
JP5808860B2 (ja) 2011-07-26 2015-11-10 ウォックハート リミテッド スルバクタム及びベータ−ラクタマーゼインヒビターを含む医薬組成物
RU2636147C1 (ru) 2011-08-27 2017-11-21 Вокхардт Лимитед Производные 1,6-диазабицикло[3,2,1]октан-7-она и их применение при лечении бактериальных инфекционных болезней
AU2012303693B2 (en) * 2011-08-30 2014-07-03 Wockhardt Limited 1,6- diazabicyclo [3,2,1] octan- 7 - one derivatives and their use in the treatment of bacterial infections
US8754102B2 (en) 2011-09-13 2014-06-17 Wockhardt Ltd. Nitrogen containing compounds and their use
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
EP2814483A2 (en) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
AU2013237869A1 (en) 2012-03-30 2014-10-23 Cubist Pharmaceuticals, Inc. Isoxazole beta-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2013149121A1 (en) 2012-03-30 2013-10-03 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
TWI565707B (zh) 2012-05-30 2017-01-11 明治製菓藥業股份有限公司 新穎β-內醯胺酶抑制劑及其製造方法
EP2961751B1 (en) 2012-08-25 2018-03-21 Wockhardt Limited 1,6- diazabicyclo [3,2,1]octan- 7- one derivatives and their use in the treatment of bacterial infections
CN104768547A (zh) 2012-09-03 2015-07-08 沃克哈特有限公司 抗菌组合物
CA2897446A1 (en) 2013-02-06 2014-08-14 Astrazeneca Ab Combination therapy for the treatment of nosocomial pneumonia
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
US9968593B2 (en) 2014-11-17 2018-05-15 Entasis Therapeutics Limited Combination therapy for treatment of resistant bacterial infections
SMT202200397T1 (it) 2016-09-16 2022-11-18 Entasis Therapeutics Ltd Composti inibitori di beta-lattamasi

Also Published As

Publication number Publication date
JP7058322B2 (ja) 2022-04-21
EA201992370A1 (ru) 2020-03-10
TWI791018B (zh) 2023-02-01
JP2020519687A (ja) 2020-07-02
HUE057592T2 (hu) 2022-05-28
EP3630111B1 (en) 2021-11-24
US11046694B2 (en) 2021-06-29
TW201843152A (zh) 2018-12-16
EP3630111A1 (en) 2020-04-08
AU2018266640B2 (en) 2022-03-03
CN110709081B (zh) 2023-09-22
PE20200333A1 (es) 2020-02-14
KR102611447B1 (ko) 2023-12-06
PH12019502509A1 (en) 2020-07-13
AU2018266640A1 (en) 2019-11-07
WO2018208769A1 (en) 2018-11-15
MX385203B (es) 2025-03-14
HRP20220231T1 (hr) 2022-04-29
MY201377A (en) 2024-02-21
IL270380B (en) 2022-06-01
CA3059773A1 (en) 2018-11-15
BR112019023130A2 (pt) 2020-05-26
KR20200005586A (ko) 2020-01-15
EA038393B1 (ru) 2021-08-20
ES2907858T3 (es) 2022-04-26
MA48743A (fr) 2020-04-08
SMT202200110T1 (it) 2022-05-12
PL3630111T3 (pl) 2022-05-23
MX2019013291A (es) 2020-01-15
SI3630111T1 (sl) 2022-05-31
LT3630111T (lt) 2022-03-10
SG11201909443YA (en) 2019-11-28
DK3630111T3 (en) 2022-03-14
US20200165251A1 (en) 2020-05-28
CN110709081A (zh) 2020-01-17
PT3630111T (pt) 2022-03-01

Similar Documents

Publication Publication Date Title
CY1125340T1 (el) Ενωσεις και μεθοδοι για αντιμετωπιση βακτηριακων λοιμωξεων
CY1124837T1 (el) Ενωσεις βενζο[β]θειοφαινιου ως αγωνιστες sting
CY1125230T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
CY1123994T1 (el) Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4
CY1124496T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
CY1122821T1 (el) Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2
CY1124031T1 (el) Ετεροαρυλ υποκατεστημενες πυριδινες και μεθοδοι χρησης
CY1124620T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
CY1122542T1 (el) Νεα παραγωγα υδροξυεστερα, μια διεργασια για την παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα
CY1124173T1 (el) Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες
CY1122340T1 (el) Αντιπολλαπλασιαστικες ενωσεις και μεθοδοι χρησης αυτων
CY1123645T1 (el) Δικυκλικα παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα
CY1123025T1 (el) Αναστολεις βρωμοεπικρατειας
CY1122560T1 (el) Νεα παραγωγα αμμωνιου, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουναυτα
CY1121884T1 (el) Αντι-ογκικες ενωσεις
CY1123069T1 (el) Νεα (ετερο)αρυλ-υποκατεστημενα-πιπεριδινυλ παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα
MX2020007392A (es) Compuestos de benzamida.
MX2018012266A (es) Amidas heterociclicas como moduladores de proteinas.
CY1120834T1 (el) Δικυκλικες αζωτουχες ενωσεις ως αγωνιστες μουσκαρινικων υποδοχεων μ1
CY1123494T1 (el) Enωσeiς etepoapyλo-kapboξamiδioy ως anaσtoλeiς thς ripk2
CY1121804T1 (el) Καινοτομες ενωσεις πυριμιδινης και πυριδινης και η χρηση τους
CY1126039T1 (el) Ενωσεις και συνθεσεις ουριας ως αναστολεις της ατρ-ασης smarca2/brm
MX390625B (es) Inhibidores selectivos de jak1.
CY1120420T1 (el) Παραγωγα σουλφονυλοπιπεριδινης και χρηση αυτων πα την αγωγη νοσων με τη μεσολαβηση προκινετισινης
CY1125198T1 (el) Ενωσεις και αναλογα 1-ετεροκυκλικου ισοχρωμανυλιου για την αντιμετωπιση διαταραχων του κνς